AEON Biopharma approves 1-for-72 reverse stock split to maintain NYSE American listing

AEON Biopharma, Inc.

Reverse split ratio of 1-for-72; effective 12:01 AM ET on February 26, 2025.
Outstanding shares reduced from ~79.9 million to ~1.1 million; fractional shares rounded up.
Authorized shares increased from 500 million to 1.04 billion at special meeting.
Ticker 'AEON' unchanged; new CUSIP 00791X 209; votes: 32.6M for, 3.6M against.
Purpose: increase share price to comply with NYSE American continued listing standards.

item 3.03 item 5.03 item 5.07 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

AEON Biopharma, Inc.: Increased authorized shares of common stock from 500,000,000 to 1,040,000,000 (effective 2025-02-25).

Change: charter amendment
Effective: 2025-02-25

Exact text from the filing

The amendment to the Certificate of Incorporation will be filed with the Secretary of State of the State of Delaware on February 25, 2025 and became effective on such date.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

AEON Biopharma, Inc.: Approved reverse stock split at a ratio of 1-for-72 (effective 2025-02-26).

Change: charter amendment
Effective: 2025-02-26

Exact text from the filing

The Company intends to file the Charter Amendment with the Secretary of State of the State of Delaware to effect the Reverse Stock Split on February 25, 2025, to become effective at 12:01 a.m. Eastern Time on February 26, 2025 (the “Effective Date”).

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-25-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.